Alaunos Therapeutics, Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Alaunos Therapeutics adopted Second Amended and Restated By-Laws effective September 16, 2026, amending bylaws from January 8, 2026. The filing contains standard governance provisions including stockholder meeting procedures, director qualifications, officer roles, indemnification rights, and forum selection (Delaware Court of Chancery for derivative and fiduciary duty claims; federal court for 1933 Act claims). No material business or financial changes disclosed.
Why this rating
Routine bylaw amendment with no business impact; administrative governance housekeeping for $9.6M market-cap company. Standard for public corporations.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.